Scaffolded Antigens in Yeast Cell Particle Vaccines Provide Protection against Systemic Polyoma Virus Infection

<div>VP1-specific (left) and GFP-specific (right) IgG titers (ELISA) in sera from bleed 5 in mice vaccinated with VP1-GFP YCPs. Vaccine was administered orally (PO) at lower (3x 400 <i>μ</i>g VP1-GFP) and higher (3x 960 <i>μ</i>g VP1-GFP) doses or subcutaneously (SQ) at a 96 <i>μ</i>g dose. Control (Ctrl) mice were not vaccinated. Red lines indicate mean values.</div>

Journal of Immunology Research

fig13

Figure 13

Figure 13: Scaffolded Antigens in Yeast Cell Particle Vaccines Provide Protection against Systemic Polyoma Virus Infection 